



**Charleston Laboratories, Inc. Appoints Kerry Segal Chief Business Development Advisor**

*Highly Analytical, Detailed and Results Oriented Executive*

**Charleston, South Carolina** – April 28<sup>th</sup> 2008 – Charleston Laboratories, Inc, an emerging specialty pharmaceutical company dedicated to reducing opioid induced nausea and vomiting (OINV) in opioid pharmaceuticals, announced today the appointment of Kerry Segal as the Chief Business Development Advisor. Mr. Segal was most recently the Global Business Development Director for Valeant Pharmaceuticals directing all business development and M&A activities. Mr. Segal has also served as in a Business Development capacity with numerous other very successful large pharmaceutical companies throughout his career.

"It is truly incredible to have Kerry as Charleston's Chief Business Development Advisor" said Paul Bosse, Chief Executive Officer of Charleston. "Mr. Segal has a distinguished track record in facilitating, structuring, and negotiating successful pharmaceutical alliances, furthermore he is very analytical, detailed and passionate when it comes to completing cutting-edge business collaborations. "Kerry's knowledge of analgesic and the CNS markets will be a tremendous resource to the Charleston management team in identifying the best opportunities for growth through partnerships all over the world and we very much look forward to his leadership in this area."

---

---

**NEWS**

---



Mr. Segal has been in the pharmaceutical/biopharmaceutical industry for the past 25 years in such capacities as field sales, market research, new product planning, competitive intelligence, strategic planning and for the past 15 years in business development (BD). His BD experience includes in-licensing, out-licensing and M&A, all on a global basis, for such companies as J&J (Ortho-McNeil), Cephalon and Valeant Pharma. Mr. Segal has closed in excess of 30 deals throughout his career, representing in-licensing, out-licensing and M&A transactions. Mr. Segal holds an MBA from Temple University.

"I am extremely excited to be working with the highly experienced and entrepreneurial management team at Charleston Labs and, hopefully develop, partner and commercialize products like CL-108 that would provide tremendous benefits to patients requiring potent pain relief" said Segal, new Chief Business Development Advisor of Charleston.



**About Charleston Laboratories, Inc.**

Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately funded specialty pharmaceutical company developing and commercializing opioid drugs with minimal or no opioid-induced nausea and vomiting (OINV). Charleston Laboratories intends to enter into discovery and commercialization alliances with partners motivated to introduce novel pain therapies that eliminate or significantly reduce nausea and vomiting.

[www.charlestonlabs.com](http://www.charlestonlabs.com).

###